Citi Boosts Colgate-Palmolive (CL) Price Target to $108 Despite Q1 Weakness | CL Stock News

Article's Main Image

Citi has increased its price target for Colgate-Palmolive (CL, Financial) from $103 to $108 while maintaining a Buy rating on the stock. This decision comes despite the company reporting underwhelming first-quarter results. According to Citi, Colgate's projected earnings cut for 2025 is less severe compared to its industry peers, which positions it favorably.

The firm expresses confidence in Colgate-Palmolive's ability to navigate tariff challenges by leveraging its strong pricing power and operational flexibility. These strategic levers are expected to help the company mitigate potential headwinds, maintaining its competitive edge in the marketplace.

Wall Street Analysts Forecast

1916807151263838208.png

Based on the one-year price targets offered by 21 analysts, the average target price for Colgate-Palmolive Co (CL, Financial) is $97.90 with a high estimate of $110.00 and a low estimate of $79.00. The average target implies an upside of 4.25% from the current price of $93.91. More detailed estimate data can be found on the Colgate-Palmolive Co (CL) Forecast page.

Based on the consensus recommendation from 24 brokerage firms, Colgate-Palmolive Co's (CL, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Colgate-Palmolive Co (CL, Financial) in one year is $91.52, suggesting a downside of 2.54% from the current price of $93.91. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Colgate-Palmolive Co (CL) Summary page.

CL Key Business Developments

Release Date: April 25, 2025

  • Tariff Impact: Incremental impact of roughly $200 million in 2025 versus initial guidance.
  • Supply Chain Investment: Approximately $2 billion invested in the U.S. supply chain over the past five years.
  • Advertising Spending: At an all-time high entering 2025.
  • Net Debt Levels: Low levels of net debt reported.
  • Profit Growth: Strong profit growth delivered despite volatility in the quarter.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Colgate-Palmolive Co (CL, Financial) has built flexibility into its plans to navigate the volatile and uncertain market environment of 2025.
  • The company is focused on delivering value-added, science-based core innovation, such as the relaunch of Colgate Total and Hill's Science Diet with ActivBiome Technology.
  • Colgate-Palmolive Co (CL) has invested approximately $2 billion in its supply chain in the United States over the past five years, enhancing its ability to adapt to changing environments.
  • The company has a strong balance sheet with low levels of net debt and plans to drive significant cash flow to fund growth and productivity.
  • Colgate-Palmolive Co (CL) has seen strong profit growth in the first quarter despite market volatility, indicating effective management and strategy execution.

Negative Points

  • The company faces challenges from weaker consumer demand and macroeconomic uncertainty, impacting volume growth.
  • Tariffs announced since January are expected to have an incremental impact of roughly $200 million in 2025, posing a financial challenge.
  • There has been a slowdown in category growth, particularly in the US and other global markets, affecting overall sales performance.
  • Colgate-Palmolive Co (CL) is experiencing some trade down from super-premium to mid-tier products in North America, indicating consumer price sensitivity.
  • The company is exiting private label production, which will be a drag on volume growth in the short term.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.